What's Going On With Silence Therapeutics Stock Today?
What's Going On With Silence Therapeutics Stock Today?
"We ended December 2023 with approximately $68.8 million and significantly increased our cash position in early 2024 to over $200 million," said Rhonda Hellums, Chief Financial Officer of Silence.Silence Therapeutics Plc (NASDAQ:SLN) shares are trading lower in the morning session on Wednesday.
Silence Therapeutics Plc（納斯達克股票代碼：SLN）股價在週三上午的交易中走低。
The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago. Collaboration revenues were £25.4 million versus £17.501 million a year ago.
該公司報告稱，2023年每股虧損爲（38.9）便士，低於去年同期的每股虧損（41.9）便士。合作收入爲2540萬英鎊，去年同期爲17501萬英鎊。
Net loss was £(43.3) million for 2023, compared to a net loss of £(40.5) million in 2022.
2023年的淨虧損爲4,330萬英鎊，而2022年的淨虧損爲4,050萬英鎊。
"We ended December 2023 with approximately $68.8 million and significantly increased our cash position in early 2024 to over $200 million," said Rhonda Hellums, Chief Financial Officer of Silence.
Silence首席財務官朗達·海勒姆斯表示：“截至2023年12月，我們的現金狀況約爲6,880萬美元，並在2024年初大幅增加到2億美元以上。”
In March 2024, Mallinckrodt (OTC:MNKTQ) notified Silence that they will not pursue further development of SLN501 following the completion of the phase 1 clinical trial. This will conclude all activities and commitments under the collaboration agreement.
2024 年 3 月，Mallinckrodt（場外交易代碼：MNKTQ）通知 Silence，在 1 期臨床試驗完成後，他們不會繼續進一步開發 SLN501。這將結束合作協議下的所有活動和承諾。
Silence also announced topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran in patients with a median baseline Lp(a) of approximately 215 nmol/L.
Silence還公佈了正在進行的針對zerlasiran的 ALPACAR-360 2期研究的36周主要數據，該研究針對中位基線Lp（a）約爲215 nmol/L的患者。
Zerlasiran was administered at 300 mg subcutaneously every 16 or 24 weeks and 450 mg every 24 weeks. The company said the study demonstrated highly significant reductions in Lp(a) compared with placebo to week 36 (primary endpoint).
Zerlasiran 每 16 或 24 周皮下給藥 300 mg，每 24 周給藥 450 mg。該公司表示，該研究表明，與安慰劑相比，Lp（a）至第36周（主要終點）顯著降低。
"We are excited to have multiple programs advancing in the clinic, supported by a substantial cash position that extends our estimated runway into 2026," Hellums added.
Hellums補充說：“我們很高興在大量現金狀況的支持下，臨床上有多個項目正在取得進展，這使我們的預計投資期延長至2026年。”
Last month, Silence Therapeutics said that the initiation by AstraZeneca PLC (NASDAQ:AZN) of phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration had triggered a $10.0 million milestone payment to the firm.
上個月，Silence Therapeutics表示，阿斯利康公司（納斯達克股票代碼：AZN）啓動了對siRNA（短干擾RNA）合作下的首個候選產品的1期臨床試驗，這引發了向該公司支付的1,000萬美元的里程碑式付款。
Price Action: SLN shares are trading lower by 5.61% to $24.45 on the last check Wednesday.
價格走勢：在週三的最後一次支票中，SLN股價下跌5.61％，至24.45美元。
Illustration of Phrama lab worker created with MidJourney.
使用 MidJourney 創作的 Phrama 實驗室工作人員的插圖。